Medivir said today it will split by year’s end into two companies—one focused on developing its drug portfolio, the other focused on commercial operations.
“The objective of the separation is to visualize the value of both the commercial operations and the pharmaceutical projects that make up the R&D portfolio,” Medivir said in a statement.
The commercial company will oversee the company’s 15 marketed drugs. One is the hepatitis C treatment Olysio® (simeprevir), an NS3/4A protease inhibitor jointly developed by Medivir and Johnson & Johnson’s Janssen R&D Ireland.
Another is Adasuve® (loxapine), an inhaled medicine for acute treatment of agitation associated with schizophrenia or bipolar I disorder. Medivir launched Adasuve in Sweden, Norway, Finland, and Denmark in 2013 under license from Ferrer—which earlier this year acquired Adasuve developer Alexza Pharmaceuticals.
Also to be marketed by the commercial company are the 13 drugs that form Medivir’s Nordic Brands Portfolio, which the company obtained through the acquisition of BioPhausia in 2011. The 13 have indications related to central nervous system (CNS), cardiovascular system, gout, musculoskeletal system, pain, respiratory system, stomach/intestine, and zinc deficiency.
The commercial company will have a separate public listing on the First North Premium exchange.
The R&D-focused company will develop Medivir’s pipeline, whose sole clinical candidate is MIV-711, a cathepsin K inhibitor indicated for the treatment of osteoarthritis. MIV-711 is the subject of a Phase IIa trial assessing the candidate in patients with moderate knee osteoarthritis. Data is expected to be available in the third quarter of 2017.
The company’s preclinical candidates include a nucleotide DNA polymerase inhibitor indicated for hepatocellular carcinoma and a respiratory syncytial virus (RSV) fusion protein inhibitor indicated for RSV infection. Discovery-phase candidates include an human immunodeficiency virus (HIV) protease inhibitor being developed in partnership with Janssen.
Earlier this month, Medivir sold rights to another preclinical candidate—MIV-802, a nucleotide-based polymerase inhibitor indicated for hepatitis C virus—to Trek Pharmaceuticals for an undisclosed price. Those rights covered most of the world, except China, Taiwan, Hong Kong, and Macau.
Medivir said it will provide additional details on the corporate split at a future capital markets day.
Source: GEN
After attending the annual Pulmonary Embolism Symposium last week in Austin, Texas, the analysts predicted clinical guidelines could shift toward catheter-based therapy once data from ongoing randomized trials is available.
SAS – the AI and analytics company – has been selected by AstraZeneca to help boost efficiency and drive automation in the delivery of statistical analyses for clinical and post-approval submissions to regulatory authorities.
After the Centers for Medicare & Medicaid Services (CMS) revealed the list of drugs set to face the first round of price negotiations under the Inflation Reduction Act (IRA), the drugmakers responsible for marketing them are confronting a series of deadlines.
